• 沒有找到結果。

Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community

N/A
N/A
Protected

Academic year: 2021

Share "Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community"

Copied!
5
0
0

加載中.... (立即查看全文)

全文

(1)

Synthesis of long-chained oligo-a-aminopyridines by tandem

Pd-catalyzed cross-coupling aminations and their helical

dinuclear complexes

Hasan Hasanov,

a,b,

Uan-Kang Tan,

b,c,

Rui-Ren Wang,

a

Gene Hsiang Lee

a

and

Shie-Ming Peng

a,b,*

aDepartment of Chemistry, National Taiwan University, Taipei, Taiwan b

Institute of Chemistry, Academia Sinica, Taipei, Taiwan

cDepartment of Chemical Engineering, Kuang Wu Institute of Technology, Taipei, Taiwan

Received 25 June 2004; revised 28 July 2004; accepted 6 August 2004

Abstract—Three novel multidentate long-chained oligo-a-aminopyridine ligands, nonapyridyloctaamine (1, npoa), decapyridylnona-amine (2, dpna), and undecapyridyldecadecapyridylnona-amine (3, upda) were synthesized successfully by tandem Pd-catalyzed cross-coupling ami-nations. The helical structures of protonated ligand npoa {4, [H4Ænpoa](SO3CF3)4} and the related dinuclear complexes 5–10 were synthesized and characterized by X-ray diffractions.

Ó 2004 Elsevier Ltd. All rights reserved.

Aminopyridines are frequently used as building blocks for synthetic transformations.1–3 On the basis of their

polynucleating abilities, their derivatives are often stud-ied in organometallic chemistry,4 and have industrial

applications such as fluorescent dyes.5,6

Oligo-a-amino-pyridines provide multidentate sites with significant flexi-bility that can produce the helical structures either by intramolecular hydrogen bond formation or self-assem-bly with metal ions into distinct binding sites. A series of a-aminopyridine ligands and various helicates have been reported, such as tetrapyridyltriamine,2

pentapyridyl-tetraamine,2 hexapyridylpentaamine,7a

heptapyridyl-hexaamine,7b and octapyridylheptaamine7c from our

laboratory, and dinuclear triple helicates from Albr-echts bis-catecholate ligands8 and Piguets

bis-terden-tate ligands;9 dinuclear double helicates from Rices

pyridylthiazole ligands10and Constables quaterpyridine

ligands.11 A key to success in assembling these helical

aminopyridines is the efficient reaction process from the halopyridines as the starting materials. The prepara-tion of aminopyridines in most studies utilized aromatic nucleophilic substitution SNAr, benzyne or SRN1

reac-tions.12,13 These methods are difficult to apply in the

consecutive synthesis of polyaminopyridines due to the poor yields, low selectivity from the nucleophilic regio-control, the high reaction temperature, and the presence of specific functionality on the heterocyclic rings.12

Buch-wald and others have recently developed cross-coupling amination to generate mono-aminopyridines starting from their corresponding halopyridines catalyzing with Pd(0)/bis-phosphine complexes.12,14,15 The advantages

of Pd-catalyzed C–N aminations are mild reaction con-ditions with high yields; hence this method is utilized to synthesize helical long-chained oligo-a-aminopyridines 1–3 effectively.

Oligo-a-aminopyridines provide multibinding capabili-ties with the metal centers, either (i) through nitrogen atoms from both pyridines and amines,16 or (ii) only

pyridines,17 or (iii) only amines, with three different

binding modes, syn–syn, anti–anti, and syn–anti (Fig. 1).18 These metal complexes are very interesting for

0040-4039/$ - see front matter Ó 2004Elsevier Ltd. All rights reserved. doi:10.1016/j.tetlet.2004.08.066

Keywords: Helical; Dinuclear metal complexes; Oligo-a-amino-pyridines.

* Corresponding author. Tel.: +886 2 23638305; fax: +886 2 23636359; e-mail:smpeng@ntu.edu.tw



These authors contributed equally.

N N N N N N N N N (a) (b) (c)

Figure 1. Types of (a) syn–syn, (b) anti–anti, (c) syn–anti. Tetrahedron Letters 45 (2004) 7765–7769

Tetrahedron

Letters

(2)

fundamental studies of special physical properties, coor-dination,19 metal–metal interactions,20–25 the assembly

of helicates,9 and biological enzymatic

transforma-tions.26–32 For example, dinickel and dicopper

com-plexes promote urease30 and oxygenase reactions,

respectively.31 Furthermore, the syn–syn conformation

was first found in linear Cu3(dpa)4Cl2,33 anti–anti

con-formation was observed in Cu(bipyam)234 and

Cu-(mpa)2,17and anti–syn conformation was only observed

in the dimers of free ligands.33 In short, the geometries

of the metal helicates are mainly controlled by the par-tition of binding sites from the ligands while linked to distinct metal centers. It is interesting to assemble long-chained oligo-a-aminopyridines, such as nonapyr-idyloctaamine (1, npoa), decapyridylnonaamine (2, dpna), and undecapyridyldecaamine (3, upda) by employing Buchwalds tandem cross-coupling amina-tion with catalyzaamina-tion by the Pd(0) complex/BINAP or DPPP, and their helical dinuclear metal complexes 5– 10. The complexes possess unique features, and have the general formula [M2(L)(ClO4)m(S)n](ClO4)oÆ(sol-vent)p where M = Ni or Cu, S = solvent, m = 0–1, n = 0–3, o = 3–4, p = 0–5.

The synthesis of novel long-chained oligo-a-aminopyr-idines 1–3 are shown in Scheme 1 where pyridine was employed as the media to replace the commonly used solvents due to its high solvating ability for the desired adducts, and successful catalyzation of the cross-cou-pling reaction.18

Ligand 1 was obtained via double Pd-catalyzed cross-coupling aminations from (A) and (B), and then subse-quent reaction with a half equivalent of 2,6-diaminopyr-idine.35A final yield of 63% was achieved. Ligand 2, in a

similar manner, was produced from (A) with an overall 41% yield via four sequential Pd-catalyzed aminations.36

Ligand 3 was prepared through a Pd-catalyzed amina-tion from bromo-substrate (E) and amino-substrate (F) in 33% yield.37 The crystal structure 4,38

[H4Ænpoa]-(SO3CF3)4, a protonated form of ligand 1, is shown in

Figure 2. It has a highly helical conformation due to its unique intramolecular hydrogen bonds (N1– H  N3, N5–H  N7, N11–H  N9, N11–H  N13, and N17–H  N15). The TGA data of ligands 1–3 show high thermal stability (500 °C), which is consistent with Jorgensons theory.3

The dinuclear metal complexes 5–10 (Fig. 4) were pre-pared by mixing 1 equiv of Ni(ClO4)2or Cu(ClO4)2with 0.55 equiv of synthetic ligands 1–3, respectively, and then growing crystals in the appropriate solvent systems by diffusion techniques. The geometry for both nickel centers demonstrate slightly distorted octahedral in the light blue compound 5 {[(Ni2npoa)(CH3CN)2(H2O)]-[ClO4]3Æ(OH)Æ(H2O)Æ(CH3CN)4} (Fig. 4),39 N(11)–N–

(12)–N(13) has a syn–syn conformation, and this molecule has a bent-helical structure (Fig. 3) with approximately 1.5 helical turns, and the full length is around 4.2 nm. The molecular structure of the deep green compound 6 {[(Cu2npoa)][ClO4]4Æ(CH3CN)3Æ (H2O)1.5}, with a distorted square planar geometry for Cu(1), and a distorted square pyramidal geometry for Cu(2),40and a regular-helical structure (Fig. 3) with a

syn–anti arrangement of N(9)–N(10)–N(11). This mole-cule shows more than two helical turns, and its full length is approximately 4.3 nm. Different coordination geometries for two nickel centers are observed in the yellowish-green compound 7 {[(Ni2dpna)(ClO4)][ClO4]3Æ (CH3NO2)Æ(CH3CN)Æ(C2H5OC2H5)2Æ(CH3OH)} where Ni(1) exhibits a distorted square pyramid geometry and Ni(2) has an octahedral shape.41The conformation

of N(7)–N(8)–N(9) has a syn–syn arrangement, and the whole molecule has a bent-helical structure with approximately two turns, and a length of around 4.8 nm. In the structure of the deep green compound 8 {[(Cu2dpna)][ClO4]4Æ(CH3OH)2} where both copper ions have distorted square pyramid geometries,42the

confor-mation of N(9)–N(10)–N(11) has a syn–syn geometry, and the whole molecule also has a bent-helical structure with approximately two turns, its full length is around

N N H H2N N Br Pd2(dba)3, BINAP, N N H N N H N NH N Br H2N N Br t-BuONa, THF Pd(PPh3)4, DPPP N N N N H N H NH2 (F) N NH2 H2N

Pd2(dba)3, BINAP, t-BuNa,, Benzene

(D) (C) t-BuONa, Pyridine Pd(PPh3)4, DPPP (E) N N H N NH N N H N Br N H N N N N N H NH dpna (2) (A) t-BuNa, Benzene 4 8 80% 85% 80% 75% N N N N H NH upda (3) 9 t-BuONa, Pyridine Pd(PPh3)4, DPPP 60% (E) N N H H2N N Br N N N Br H (B) Pd2(dba)3, BINAP t-BuONa, Benzene (A) t-BuONa, THF Pd(PPh3)4, DPPP N N N N H N H (C) npoa (1) N N H N N H N N H N Br N NH2 H2N 7 1/2 90% 70% Scheme 1.

Figure 2. The ORTEP structure of the cationic part in compound 4, thermal ellipsoids 30% probability level.

(3)

4.6 nm. The geometry for the nickel ions in the yellow-ish-orange compound 9, {[(Ni2upda)][ClO 4]4Æ(CH3-NO2)Æ(CH3OH)3.5} where Ni(1) has a distorted square pyramid geometry and Ni (2) exhibits an octahedral shape;43 N(11)–N(12)–N(13) has a syn–syn

conforma-tion, and the whole molecule has a bent-helical struc-ture with more than two turns, its rough length is around 5.2 nm. Both copper ions have distorted square planer shapes (Fig. 4)44 in the deep green compound

10 {[(Cu2upda)][ClO4]4Æ(CH2Cl2)0.5Æ(CH3NO2)4Æ(H2O)3}, and all the nitrogen linkage arrangements have anti–anti conformations, the whole molecule has a regular-heli-cal structure with more than three complete turns, and its rough length is around 5.8 nm.

The magnetic properties were measured using ground powders of the dinuclear compounds 5–1035–40 (at

10 kG), and a simple spin-only model of magnetic moment (leff)45 was adapted due to their long metal–

metal distances. The leff= [n1(n1+ 2) + n2(n2+ 2)] 1/2

, where n1 represents the unpaired electrons of metal (1), and n2 represents the unpaired electrons of metal (2), was calculated. Dinickel compounds 5, 7, and 9 have leff= 3.9, 4.0, and 4.2, respectively, that are close to the high spin predicted value, leff= [2(2 + 2) + 2(2 + 2)]1/2= 4.0. The dicopper compounds 6, 8, and 10 all

have leff= 2.3, which agrees with the predicted value leff= [1(1 + 2) + 1(1 + 2)]1/2= 2.4. The magnetic studies have revealed that the dinickel complexes (5, 7, and 9) exhibit a slight antiferromagnetic behavior at tempera-ture < 50 K, and paramagnetic properties at all other tested temperatures. The dicopper complexes (6, 8, and 10) show paramagnetic behaviors at all recorded tem-peratures. This indicates that these magnetic behaviors for the dinuclear complexes are actually similar to their corresponding mononuclear complexes. The paramag-netic behaviors are also consistent with the NMR obser-vations where the downfield peaks occur at 10–20 ppm for metal complexes versus their corresponding free ligands.

This work reports the effective synthesis of novel helical oligo-a-aminopyridine ligands 1–3 by tandem Pd-cata-lyzed cross-coupling amination, and their correspond-ing dinuclear (Ni2+/Ni2+ and Cu2+/Cu2+) metal complexes 5–10. Ligands 1–3 show coordination to the metal centers only through the nitrogen atoms on the pyridine rings. Only dinuclear complexes 6 and 10 show regular-helical structures and with weak p–p interac-tions. It is worthwhile to note that the dinuclear com-plexes 5–10 exhibit the longest metal–metal distances that have been reported for complexes with oligo-a-ami-nopyridine ligands, with distances between the metal centers of 6.042, 4.639, 6.231, 5.836, 5.900, and 7.420 A˚, respectively.

Crystallographic data for the structural analysis have been registered in the Cambridge Crystallographic Data Center: compound 4 was registered as CCDC No. 201554, compound 5 as CCDC No. 201556, compound 6 as CCDC No. 201555, compound 7 as CCDC No. 201558, compound 8 as CCDC No. 201557, compound 9 as CCDC No. 201560, and compound 10 as CCDC No. 201559. Information may be obtained free of charge from the Director, CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK (fax: +44-1223-336033; e-mail: depos-it@ccdc.cam.ac.uk orhttp://www.ccdc.cam.ac.uk).

Acknowledgements

We thank the National Science Council and the Minis-try of Education of the Republic of China for the finan-cial supports.

References and notes

1. Textbook of Organic Medicinal and Pharmaceutical Chem-istry; Delgado, J. N., Gisvold, O., Remers, W. A., Eds.; Lippincott-Raven: Philadelphia, PA, 1998; p 666. 2. Peng, C.-H.; Wang, C.-C.; Lee, H.-C.; Lo, W.-C.; Lee,

G.-H.; Peng, S.-M. J. Chin. Chem. Soc. (Taipei) 2001, 48, 987–996.

3. Leung, M.-K.; Mandal, A. B.; Wang, C. C.; Lee, G.-H.; Peng, S.-M.; Cheng, H.-L.; Her, G.-R.; Chao, I.; Lu, H.-F.; Sun, Y.-C.; Shiao, M.-Y.; Chou, P.-T. J. Am. Chem. Soc. 2002, 124, 4287–4297.

4. (a) Yang, M.-H.; Lin, T.-W.; Chou, C.-C.; Lee, H.-C.; Chang, H.-C.; Lee, G.-H.; Leung, M.-K.; Peng, S.-M.

Figure 4. The ORTEP structure of cationic part of 5 {[(Ni2

-npoa)(CH3CN)2(H2O)][ClO4]3Æ(OH)Æ(H2O)Æ(CH3CN)4, 30%}, 6 {[(Cu2

-npoa)][ClO4]4Æ(CH3CN)3Æ(H2O)1.5, 50%}, 7 {[(Ni2dpna)(ClO4)][ClO4]3Æ

(CH3NO2)Æ(CH3CN)Æ(C2H5OC2H5)2Æ(CH3OH), 30%}, 8 {[(Cu2

dpna)]-[ClO4]4Æ(CH3OH)2, 50%}, 9 {[(Ni2upda)][ClO4]4Æ(CH3NO2)Æ(CH3

-OH)3.5, 30%}, 10 {[(Cu2upda)][ClO4]4Æ(CH2Cl2)0.5Æ(CH3NO2)4Æ(H2O)3,

(4)

J. Chem. Soc., Chem. Commun. 1997, 2279–2280; (b) Lai, S.-Y.; Lin, T.-W.; Chen, Y.-H.; Wang, C.-C.; Lee, G.-H.; Yang, M.-H.; Leung, M.-K.; Peng, S.-M. J. Am. Chem. Soc. 1999, 121, 250–251; (c) Chang, H.-C.; Li, J.-T.; Wang, C.-C.; Lin, T.-W.; Lee, H.-C.; Lee, G.-H.; Peng, S.-M. Eur. J. Inorg. Chem. 1999, 1243–1251; (d) Basuli, F.; Peng, S.-M.; Bhattacharya, S. Inorg. Chem. 2001, 40, 1126–1133.

5. Araki, K.; Mutai, T.; Shigemitsu, Y.; Yamada, M.; Nakajima, T.; Kuroda, S.; Shimao, I. J. Chem. Soc., Perkin. Trans. 2 1996, 613–617.

6. Sathyamoorthy, G.; Soong, M. L.; Ross, T. W.; Boyer, J. H. Heteroatom. Chem. 1993, 4, 603–608.

7. (a) Lee, C.-C. Master Thesis, Taiwan University, May, 2000; pp 26–42; (b) Lin, Y.-S. Master Thesis, Taiwan University, May, 2000; pp 29–42; (c) Unpublished labo-ratory data.

8. Albrecht, M. Chem. Soc. Rev. 1998, 27, 281–287. 9. Elhabiri, M.; Scopelliti, R.; Bunzli, J.-C. G.; Piguet, C.

J. Am. Chem. Soc. 1999, 121, 10747–10762.

10. (a) Rice, C. R.; Wo¨rl, S.; Jeffery, J. C.; Paul, R. L.; Ward, M. D. J. Chem. Soc., Dalton. Trans. 2001, 550–559; (b) Rice, C. R.; Wo¨rl, S.; Jeffery, J. C.; Paul, R. L.; Ward, M. D. J. Chem. Soc., Chem. Commun. 2000, 23, 1529– 1530.

11. Constable, E. C.; Elder, S. M.; Hannon, M. J.; Martin, A.; Raithby, P. R.; Tocher, D. A. J. Chem. Soc., Dalton. Trans. 1996, 2423–2433.

12. (a) Miyazaki, Y.; Kanbara, T.; Yamamoto, T. Tetrahe-dron Lett. 2002, 43, 7945–7948; (b) Kosugi, M.; Kawey-ama, M.; Migita, T. Chem. Lett. 1983, 927–933; (c) Louie, J.; Hartwig, J. F. Tetrahedron Lett. 1995, 36, 3609–3612; (d) Hartwig, J. F. Angew. Chem., Int. Ed. 1998, 37, 2046– 2067.

13. March, J. Advanced Organic Chemistry; John Wiley and Sons: New York, NY, 1985; 576.

14. Wagaw, S.; Buckwald, S. L. J. Org. Chem. 1996, 61, 7240– 7241.

15. Wolfe, J.; Buckwald, S. L. J. Org. Chem. 2000, 65, 1144– 1157.

16. Cotton, F. A.; Daniels, L. M.; Murillo, C. A.; Pascual, I.; Zhou, H.-C. J. Am. Chem. Soc. 1999, 121, 6856– 6861.

17. Baxter, C. E.; Rodig, O. R.; Schlatzer, R. K.; Sinn, E. Inorg. Chem. 1979, 18, 1918–1921.

18. Hasanov, H.; Tan, U.-K.; Lin, Y.-S.; Lee, C.-C.; Lee, G.-H.; Lin, T.-W.; Peng, S.-M. Inorg. Chim. Acta 2003, 351, 369–377.

19. Lai, S.-Y.; Wang, C.-C.; Chen, Y.-H.; Lee, C.-C.; Liu, Y.-H.; Peng, S.-M. J. Chin. Chem. Soc. (Taipei) 1999, 46, 477–485.

20. Cotton, F. A.; Czuchajowska, J.; Feng, X. Inorg. Chem. 1990, 29, 4329–4335.

21. Wu, L. P.; Field, P.; Morrisey, T.; Murphy, C.; Nagle, P.; Hathaway, B.; Simmons, C.; Thornton, P. J. Chem. Soc., Dalton. Trans. 1990, 3835–3840.

22. Pyrka, G. J.; El-Mekki, M.; Prinkerton, A. A. J. Chem. Soc., Chem. Commun. 1991, 84–85.

23. Aduldecha, A.; Hathaway, B. J. Chem. Soc., Dalton. Trans. 1991, 993–998.

24. (a) Cotton, F. A.; Daniels, L. M.; Murillo, C. A.; Pascual, I. J. Am. Chem. Soc. 1997, 119, 10223–10224; (b) Cotton, F. A.; Daniels, L. M.; Murillo, C. A.; Wang, X. P. J. Chem. Soc., Chem. Commun. 1998, 23, 39– 40.

25. Sheu, J.-T.; Liu, C.-C.; Chao, I.; Wang, C.-C.; Peng, S.-M. J. Chem. Soc., Chem. Commun. 1996, 23, 315–316. 26. Poyner, R. R.; Reed, G. H. Biochemistry 1992, 31, 7166–

7173.

27. Reczkowski, R. S.; Ash, D. E. J. Am. Chem. Soc. 1992, 114, 10992–10994.

28. Vincent, J. B.; Crowder, M. W.; Averill, B. A. Trends Biochem. Sci. 1992, 17, 105–110.

29. Roderick, S. L.; Matthews, B. W. Biochemistry 1993, 32, 3907–3912.

30. Day, E. P.; Peterson, J.; Sendova, M. S.; Todd, M. J.; Hausinger, R. P. Inorg. Chem. 1993, 32, 634–638. 31. Karlin, K. D.; Hayes, J. C.; Gultneh, Y.; Cruse, R. W.;

McKown, J. W.; Hutchinson, J. P.; Zubieta, J. J. Am. Chem. Soc. 1984, 106, 2121–2128.

32. (a) Burley, S. K.; Daivid, P. R.; Taylor, A.; Lipscomb, W. N. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 6878–6882; (b) Burley, S. K.; David, P. R.; Lipscomb, W. N. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6916–6920.

33. Yang, E.-C.; Cheng, M.-C.; Tsai, M.-S.; Peng, S.-M. J. Chem. Soc., Chem. Commun. 1994, 2377–2378. 34. Rodig, O. R.; Brueckner, T.; Huriburt, B. R.; Schlatzer,

R. K.; Benable, T. L.; Sinn, E. J. Chem. Soc., Chem. Commun. 1981, 196–198.

35. npoa, nonapyridyloctaamine, 1: Anal. Calcd for C45H37N17: C 66.25, H 4.57, N 29.18. Found: C 66.36, H 4.56, N 29.08. IR (KBr): 3408, 3310, 3205, 3021, 1674, 1582, 1431, 1307, 1149, 1774, 1149, 715 cm1. 1H NMR (400 MHz, DMSO-d6): d 9.38 (s, 2H, NH), 9.09 (s, 6H, NH), 6.83–8.21 (m, 29H, aromatic H). FAB/MS [m/z]: [816 (M)+].

36. dpna, decapyridylnonaamine, 2: Anal. Calcd for C50H41N19: C 66.14, H 4.55, N 29.31. Found: C 66.43, H 4.42, N 29.15. IR (KBr): 3448, 3310, 3198, 1635, 1562, 1516, 1418, 1352, 1155 cm1.1H NMR (400 MHz, DMSO-d6): d 8.49 (s, 2H, NH), 8.20 (s, 7H, NH), 5.99–7.35 (m, 32H, aromatic H). FAB/MS [m/z]: [908 (M)+].

37. upda, undecapyridyldecaamine, 3: Anal. Calcd for C55H45N21: C 66.05, H 4.54, N 29.41. Found: C 66.30, H 4.38, N 29.32. IR (KBr): 3416, 3204, 2952, 1587, 1514, 1434, 1308, 778 cm1.1H NMR (400 MHz, DMSO-d 6): d 9.36 (s, 2H, NH), 9.06 (s, 8H, NH), 6.84–8.20 (m, 35H, aromatic H). FAB/MS [m/z]: [1000 (M)+].

38. Crystallographic data for 4: C52H45.50F12N18.50O12S4, M = 1477.81, monoclinic, space group C2/c, a = 26.5696 (11), b = 14.6662 (6), c = 33.9125 (14), a = 90°, b = 111.3060° (10), c= 90°, V = 12311.7 (9) A˚3, Z = 8, Dcalcd= 1.595 g/cm3, l(MoKa) = 0.268 mm1, k = 0.71073A˚ , T = 150 (1) K, h= 1.29–26.43°, Tmin/Tmax= 0.8562/ 0.9280, independent reflns. = 12606 (Rint= 0.0850), Rf= 0.0549, GOF = 1.059. The structure was solved in Bruker SMART by direct method and expanded by using Fourier techniques, the functions were minimized during least-squares cycles where R = RjjF0jjFcjj/RjF0j; ðF2

0Þ ¼ ½RfwðF20 F2cÞ

2g=RfwðF2 0Þ

2g 1=2. The nonhydro-gen atoms were refined anisotropically.

39. Crystallographic data for 5: C57H60Cl3N23Ni2O15, M = 1531.05, triclinic, space group P1, a = 11.8920 (6), b = 13.8128 (7), c = 22.5784(12), a = 83.140° (1), b = 83.697° (1), c = 86.049° (1), V = 1852.83 (3) A˚3, Z = 2, Dcalcd= 1.392 g/cm3, l(MoKa) = 0.701 mm1, k= 0.71073 A˚ , T = 150 (1) K, h= 0.91–26.37°, Tmin/Tmax= 0.6904/ 0.8621, independent reflns. = 14936 (Rint= 0.0881). Rf= 0.0896, GOF = 1.024. The structure was solved in Bruker SMART with the same method described previously. 40. Crystallographic data for 6: C51H49Cl4N20Cu2O17.50,

M = 1490.98, monoclinic, space group P21/c, a = 22.3833 (12), b = 13.1494 (7), c = 20.6251 (11), a = 90°, b = 101.995° (1), c = 90°, V = 5938.0 (5) A˚3

, Z = 4 , Dcalcd= 1.668 g/cm3, l(MoKa) = 0.987 mm1, k= 0.71073 A˚ , T = 150 (1) K, h = 2.43–27.50°, Tmin/Tmax= 0.7154/ 0.8311, independent reflns. = 13624(Rint= 0.0331). Rf= 0.0451, GOF = 1.014. The structure was solved in

(5)

Bruker SMART with the same method described previously.

41. Crystallographic data for 7: C62H71Cl4N21Ni2O21, M = 1705.62, triclinic, space group P1, a = 14.6520 (1), b = 15.4574 (1), c = 17.5339 (2), a = 100.7550° (4), b = 98.3837° (4), c = 110.4784° (4), V = 3557.37 (5) AA3, Z = 2, Dcalcd= 1.592 g/cm3, l (MoKa) = 0.770 mm1, k = 0.71073 A˚ , T = 150 (1) K, h = 2.43–27.50°, Tmin/Tmax= 0.774/0.942, independent reflns. = 16291 (Rint= 0.0662). Rf= 0.0665, GOF = 1.021. The structure was solved in Nonius KappaCCD with the same method described previously.

42. Crystallographic data for 8: C52H49Cl4N19Cu2O18, M = 1496.98, monoclinic, space group P21/c, a = 15.4476 (3), b = 14.4702 (2), c = 25.9158 (6), a = 90°, b = 98.3837° (4), c = 90°, V = 5735.39 (19) A˚3, Z = 4 , D

calcd= 1.734g/ cm3, l(MoK

a) = 1.022 mm1, k = 0.71073 A˚ , T = 150 (1) K, h = 1.92–25°, Tmin/Tmax= 0.5449/0.8950, independent reflns. = 10088 (Rint= 0.0768). Rf= 0.0546, GOF = 1.051. The structure was solved in Nonius KappaCCD with the same method described previously.

43. Crystallographic data for 9: C59.50H62Cl4N22Ni2O21.50, M = 1688.53, monoclinic, space group P21/n, a = 11.0634 (1), b = 24.8780 (2), c = 25.0143 (2), a = 90°, b = 101.0158° (3), c = 90°, V = 6757.96 (10) A˚3, Z = 4 , Dcalcd= 1.660 g/ cm3, l(MoKa) = 0.811 mm1, k = 0.71073 A˚ , T = 150 (1) K, h = 1.8427.50°, Tmin/Tmax= 0.646/0.931, independent reflns. = 15455 (Rint= 0.0581). Rf= 0.0826, GOF = 1.040. The structure was solved in Nonius KappaCCD with the same method described previously.

44. Crystallographic data for 10: C59.50H64Cl5N25Cu2O27, M = 1865.69, monoclinic, space group P21/n, a = 11.6942 (2), b = 26.4115 (5), c = 25.0251 (5), a = 90° (1), b = 99.730° (1), c = 90°, V = 7618.1 (2) A˚3

, Z = 4 , Dcalcd= 1.627 g/cm3, l(MoKa) = 0.832 mm1, k = 0.71073 A˚ , T = 150 (1) K, h = 2.07–25°, Tmin/Tmax= 0.830/0.974, inde-pendent reflns. = 13385 (Rint= 0.0747). Rf= 0.1624, GOF = 1.058. The structure was solved in Non-ius KappaCCD with the same method described previously.

45. Teweldemedhin, Z. S.; Fuller, R. L.; Greenblatt, M. J. Chem. Edu. 1996, 73, 906–909.

數據

Figure 1. Types of (a) syn–syn, (b) anti–anti, (c) syn–anti.
Figure 2. The ORTEP structure of the cationic part in compound 4, thermal ellipsoids 30% probability level.
Figure 4. The ORTEP structure of cationic part of 5 {[(Ni 2 - -npoa)(CH 3 CN) 2 (H 2 O)][ClO 4 ] 3 Æ(OH)Æ(H 2 O)Æ(CH 3 CN) 4 , 30%}, 6 {[(Cu 2  -npoa)][ClO 4 ] 4 Æ(CH 3 CN) 3 Æ(H 2 O) 1.5 , 50%}, 7 {[(Ni 2 dpna)(ClO 4 )][ClO 4 ] 3 Æ (CH 3 NO 2 )Æ(CH 3 CN)Æ

參考文獻

相關文件

The chairman/representative director, and at least 2/3 of the board of directors of a limited company or a company limited by shares providing the above services shall be the

• Step 2: Run DFS on the transpose

• Step 2: Run DFS on the transpose

Consistent with the negative price of systematic volatility risk found by the option pricing studies, we see lower average raw returns, CAPM alphas, and FF-3 alphas with higher

1st. To make a study of the routes followed by Huien Tsang and Sudhadana in India. To study the geography, geology, climate and connections of those routes in order to assess

▪ Step 2: Run DFS on the transpose

(4) If a live-in foreign worker tests positive after a rapid COVID-19 test or a PCR test and is isolated or hospitalized and on leaving hospital subject to home quarantine, home

Owing to the pandemic of novel coronavirus pneumonia, Visitor Expenditure Survey was suspended in the 2 nd quarter of 2020, and thus no information is released for this